Lacosamide Sandoz

Lacosamide, the active ingredient in Lacosamide Sandoz, is an anti‑epileptic presented as an oral tablet for oral use. It is used as adjunctive therapy to reduce the frequency of partial‑onset seizures in patients with epilepsy. It belongs to the class of sodium channel modulators and is indicated for patients whose seizures are not adequately controlled by other antiepileptic drugs.

GNH USA supplies Lacosamide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable supply chains across multiple continents.

Lacosamide is an anti‑epileptic drug used as adjunctive therapy for focal seizure disorders.

- Partial‑onset (focal) seizures: Reduces seizure frequency when added to existing antiepileptic therapy. - Focal seizures with secondary generalization: Helps control seizure spread in patients with refractory epilepsy. - Adjunctive therapy in epilepsy: Improves overall seizure management for patients not adequately controlled by monotherapy.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: Light‑headed sensation, often occurring at treatment initiation. - Headache: Mild to moderate intensity, usually transient. - Nausea: Gastrointestinal discomfort that may improve with continued use. - Fatigue: Generalized tiredness or reduced energy levels.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation that can lead to arrhythmias. - Suicidal thoughts or behavior: Emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate medical attention.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal impairment: Adjust dose if severe kidney dysfunction is present. - Hepatic impairment: Use with caution in patients with liver disease. - Cardiac conduction: Monitor ECG for PR‑interval prolongation. - Concomitant antiepileptic drugs: Assess for additive CNS depression. - Pregnancy and lactation: Use only if benefit outweighs risk. - Store at ambient temperature: Keep below 25 °C, protect from moisture and light in original packaging.

Lacosamide can interact with several medicines, requiring careful assessment.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May reduce lacosamide plasma levels. - Co‑administration with other sodium channel blockers (e.g., lamotrigine, oxcarbazepine): Increases risk of CNS depression. - Combination with drugs that prolong PR interval (e.g., verapamil): May cause cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Use with other antiepileptic drugs (e.g., valproate, topiramate): May require dose adjustments. - Concurrent use of alcohol or CNS depressants: May enhance dizziness and sedation. - Interaction with anticoagulants (e.g., warfarin): Monitor INR as lacosamide may affect bleeding risk.